Summary
XBI Chart
People also search for
XBI: Big Pharma Can Keep The 76% Rally Going
State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally. XBI's modified equal-weight structure offers broad exposure to over 150 biotech names, benefiting from ongoing M&A and improved capital access. Recent large-cap pharma acquisitions and selective capital flows support XBI's thesis, though volatility remains high and returns are likely to moderate.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)
State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI's under-20x earnings multiple and diversified holdings support a constructive outlook.
SPDR S&P Biotech ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 8,246 | $835,285.38 | $1.24M | $399,800.5 | 47.86% |
 Curtis Ellergodt Rothschild Investment LLC | 8,382 | $803,134.19 | $1.23M | $427,091.95 | 53.18% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 82,119 | $13M | $12.05M | -$942,742.37 | -7.25% |
 Means Investment Company Means Investment Company Inc. | 6,640 | $635,708.11 | $967,049.6 | $331,341.49 | 52.12% |
| PN Peter Nicholson First Bancorp Inc. /ME/ | 482 | $76,276.5 | $69,499.58 | -$6,776.92 | -8.88% |
SPDR S&P Biotech ETF (XBI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has SPDR S&P Biotech ETF ever had a stock split?
SPDR S&P Biotech ETF Profile
| ARCA Exchange | US Country |
Overview
The provided company is a financial entity that focuses on mirroring the performance of the S&P Biotechnology Select Industry Index. By employing a sampling strategy, the fund aims to invest predominantly, if not entirely, in the components that make up the index. This index is a representation of the biotechnology segment of the S&P Total Market Index (S&P TMI), encompassing companies within the biotechnology industry. The strategy includes investing at least 80% of its total assets in the securities that form part of the index, ensuring a strong alignment with the biotechnology sector's market movements.
Products and Services
- Biotechnology Industry Index Fund
This product is designed for investors seeking exposure to the biotechnology sector. The fund tracks the S&P Biotechnology Select Industry Index, which is a subset of the larger S&P Total Market Index (S&P TMI) focused specifically on the biotechnology industry. By putting a significant portion of its assets—substantially all, but at a minimum, 80%—into the securities that compose the index, the fund offers a direct pathway for investment in a diversified portfolio of biotechnology companies. The sampling strategy employed aims to replicate the index's performance, making it an attractive option for those looking to invest in the biotechnology industry through a mechanism that mirrors its market dynamics closely.
Contact Information
